Emerging Therapies for Soft-Tissue Sarcomas - 03/10/13
Résumé |
Sarcomas are heterogeneous group of tumors that arise from tissues of mesenchymal origin. Current options for patients with advanced disease are limited, and only 2 drugs have been approved for these diseases over the last decade. Although several drugs are currently under development for soft-tissue sarcoma as a whole, improved understanding of sarcoma biology has led to the emergence of subtype-specific targeted therapy. This article reviews recent clinical data on emerging therapies for soft-tissue sarcoma.
Le texte complet de cet article est disponible en PDF.Keywords : Sarcoma, Tumor, Cancer, Therapy, Drug development
Plan
| Disclosures: AL, LT, and PAC's institution have received research funding from Novartis and Roche. PAC is a coordinating investigator for Novartis and Roche sponsored trials. PAC has received travel reimbursment from Novartis, Roche, PharmaMar. PAC has recevied Honoraria from Novartis, Servier, Glaxo Smith Kline, and PharmaMar. |
Vol 27 - N° 5
P. 1063-1078 - octobre 2013 Retour au numéro
Article précédent
- Targeted Therapies in Rare Sarcomas : IMT, ASPS, SFT, PEComa, and CCS
- Silvia Stacchiotti, Andrea Marrari, Angelo P. Dei Tos, Paolo G. Casali
- Index
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?